|
|
||||||||









* Partners AIDS Research Center and Infectious Disease Division, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114;
Childrens Hospital, Boston, MA 02115;
Nuffield Department of Medicine, John Radcliffe Hospital, Oxford, United Kingdom;
Howard Hughes Medical Institute, Harvard Medical School, Boston, MA 02115; ¶ Centre for Clinical Immunology and Biomedical Statistics, Royal Perth Hospital, Perth, Australia; || Boston Medical Center, Boston, MA 02118;# Queen Elizabeth Hospital, Bridgetown, Barbados; and ** National Cancer Institute, HIV and AIDS Malignancy Branch, Bethesda, MD 20892
| Abstract |
|---|
|
|
|---|
| Introduction |
|---|
|
|
|---|
Escape within targeted viral epitopes can provide strong evidence of effective immune-mediated selection pressure; indeed, the marked heterogeneity of HIV-1 is attributable in large part to the class I HLA-restricted CTL response (9). While CTL escape is common among HIV-infected adults, escape during infancy has not been described previously. Although HIV-specific CTL clones have been isolated from cord blood (10), several studies suggest that in general HIV-specific CTLs are later to emerge and lower in frequency among infants than adults (10, 11, 12). Moreover, HIV-specific CTL responses primed during infancy appear to be less durable in the absence of sustained antigenic exposure, because early antiviral therapy leads to the disappearance of these responses among infants but not adults (11). It remains to be determined whether infants are able to mount fully functional HIV-specific CTL responses that are capable of exerting immune selection pressure.
To determine the extent and consequences of viral escape during early childhood, we examined the immune response to a HIV-1 epitope (TW10-Gag; TSTLQEQIGW) that is known to be targeted very early by adult subjects expressing HLA-B57 (13), an allele associated with exceptionally low HIV-1 viral loads and delayed progression to AIDS (14). Escape from TW10 and other B57-restricted HIV-1 epitopes was observed to occur early during the course of perinatal HIV-1 infection, indicating that CTL responses generated during infancy are sufficiently potent to drive viral evolution. Moreover, we present evidence that the maturing immune system of children demonstrates greater plasticity in immune recognition and is able to mount a strong response to a variant epitope following CTL escape, which is not observed among adults in whom these same variants arise.
| Materials and Methods |
|---|
|
|
|---|
Perinatally HIV-1-infected children expressing HLA-B57 or the closely related B5801 allele were recruited at the Boston Medical Center and Childrens Hospital (Boston, MA), the National Cancer Institute (Bethesda, MD), and the Queen Elizabeth Hospital (Bridgetown, Barbados). Biological parents, when available, were also approached to consent for blood sampling. Additional HIV-1-infected adult control subjects were recruited at Massachusetts General Hospital and the Royal Perth Hospital. Additional plasma samples were obtained for viral sequencing from HIV-infected children in the Hemophilia Growth and Development Study (CH-15 to CH-20). This study was approved by the Institutional Review Board at all participating institutions, and all subjects and/or legal guardians signed written informed consent before participation.
Class I HLA typing
Class I HLA typing was performed by DNA PCR with sequence-specific primers (Dynal Biotech). HIV-1 peptides were synthesized on an automated peptide synthesizer using Fmoc chemistry at the Peptide Core Facility at the Massachusetts General Hospital.
ELISPOT assays
Fresh PBMC were plated in R10 medium at 100,000 cells/well with peptides at concentrations ranging from 104 to 10 10 M. Plates were incubated overnight and processed by standard methods (15). Individual IFN-
-secreting cells were counted using the AID EliSpot Reader System (Cell Technology). Results were calculated as the number of spot-forming cells per million input cells after subtraction of background.
Sequencing of HIV-1 RNA
Sequencing of HIV-1 RNA was performed from plasma following amplification of gag and nef by nested PCR (primers and conditions previously described) (15). PCR products of the secondary reaction were purified and sequenced directly on an ABI 3100 DNA Analyzer from Applied Biosystems. In addition, clonal sequence analysis was performed on longitudinal plasma samples from mother-child pairs CH-05/M-05 and CH-06/M-06 using the Topo-TA vector system (Invitrogen Life Technologies).
Peptide-specific clones
Peptide-specific clones were generated as described previously (16). Briefly, PBMC were plated at limiting dilution with allogeneic feeder cells and the anti-CD3 Ab 12F6 in the presence of IL-2. Wells were screened for specific recognition of HLA-matched, peptide-pulsed, 51Cr-labeled B cell targets after 21 days in culture, and wells showing high specific recognition of the relevant peptide were then transferred to 24-well plates and restimulated with 106 feeder cells, 12F6, and IL-2. Expanded wells were retested for lytic activity after 14 days by 51Cr release assay using HLA-matched B cell line targets.
Statistical analysis
Statistical analyses were performed using Stata Statistical Software, Release 8.0 (StataCorp). Categorical variables were compared using Fishers exact test. All tests were two-tailed, with p < 0.05 considered significant.
| Results |
|---|
|
|
|---|
Among B57+ adults with primary HIV-1 infection, the Gag epitope TSTLQEQIGW (TW10) dominates the early CTL response (13), resulting in nearly universal escape during the early stages of infection (17). To determine whether similar immune selection pressure is present in perinatally HIV-1-infected children, we assessed recognition of TW10 and other B57-restricted HIV-1 epitopes in an IFN-
ELISPOT assay among 14 children and 34 adults expressing HLA-B57 or the closely related B5801 allele, which presents many of the same epitopes, including TW10 (18). The TW10 epitope was recognized by 83% of acutely HIV-1-infected adults (n = 12) and 50% of chronically infected adults (n = 22), consistent with a waning response following escape during the acute phase of infection. However, recognition of this epitope was much less frequent among pediatric subjects, with only 7% of children (n = 14), demonstrating an IFN-
response (Fig. 1; p = 0.0005). Recognition of the other B57-restricted HIV-1 epitopes listed in the Los Alamos HIV Immunology Database (
www.hiv.lanl.gov
) did not statistically differ between children and adults in this cohort (Fig. 2).
|
|
To determine whether sequence variation within TW10 contributes to its infrequent recognition by children, we sequenced viral isolates from the 14 pediatric subjects referenced above and 7 additional B57/5801-positive children from whom plasma was available. All 21 children demonstrated mutations in TW10, principally at positions 3 and 9 within the epitope (Gag HXB2 residues 242 and 248), where sequence variation has been shown to be strongly associated with expression of HLA-B57 or 5801 (17) (Table I). In particular, the threonine-to-asparagine substitution at position 3 (T242N), present in 18 of 21 children, is exceedingly rare among chronically HIV-1-infected adults who lack these alleles (0 of 187 subjects) (17). Therefore, the frequent presence of these mutations in our pediatric cohort provides strong evidence of B57-mediated immune selection pressure.
|
Frequent early escape from B57-restricted epitopes during infancy
Although an ex vivo response to TW10 could be demonstrated in only one child, the universal presence of TW10 escape mutations in children born to B57/5801-negative mothers suggested that a CTL response to this epitope was present in these children at an earlier point in time and drove viral escape. To establish the existence of a memory response to the original TW10 epitope in one such child, we sought CTL clones specific for the wild-type TW10 epitope in the 4-year-old subject CH-05, who developed two escape mutations (T242N and G248A) within TW10 before 24 mo of age, following vertical transmission of the wild-type epitope from his B57-negative mother. We derived seven CTL clones from this child that were specific for the wild-type TW10 epitope and only weakly cross-reactive against the autologous N3A9 variant (Fig. 3A). Of note, PBMC obtained from this child at the same time point failed to recognize the wild-type TW10 epitope, but a response to the autologous N3A9 variant was readily demonstrable ex vivo (Fig. 3B). The successful derivation of CTL clones specific for the wild-type TW10 epitope in this subject demonstrates that a memory CTL population specific for the original wild-type TW10 epitope persists at low frequency despite the occurrence of CTL escape.
|
|
To follow up on the unexpected observation of an ex vivo CTL response to the autologous N3A9 variant following TW10 escape in subject CH-05 (Fig. 2), we assessed the ability of CTL from other B57/5801-positive children to recognize TW10 epitope variants following escape. Recognition of the wild-type TW10 epitope, the autologous escape variant, and other commonly occurring variants were compared in an IFN-
ELISPOT assay in all children from whom sufficient cells were available (subjects CH-01 to CH-13). Surprisingly, most children (9 of 13) demonstrated a robust response to the autologous variant epitope while recognizing the wild-type TW10 epitope weakly or not at all (Fig. 4). In several cases these variant-specific T cells were of very high frequency, representing one of the two immunodominant B57- or B5801-restricted responses in subjects CH-04, -06, -09, and -13. In all but the youngest child, the autologous variant was recognized with higher avidity than all other TW10 variants tested. This child (CH-06) instead preferentially recognized the variant bearing a single position 9 substitution (G248A) that arose at 14 mo of age, although he has since developed an additional mutation at position 3 (T242N). All four subjects who lacked a variant-specific response also failed to recognize the wild-type TW10 epitope; two of these subjects had nondetectable viremia on HAART3 and weak overall HIV-1-specific CTL activity. Of note, strong recognition of the autologous TW10 variant was observed in the majority of children who inherited the B57/5801 allele paternally (four of six), as well as those who inherited the allele maternally. Therefore, strong variant-specific responses are not merely due to priming by maternally transmitted escape variants but are also generated in children who were infected originally with the wild-type TW10 epitope and subsequently escaped.
|
|
The spectrum of TW10 escape mutations observed among adults subjects resembled that of our pediatric cohort, with T242N and/or G248A representing the most common variants. However, a higher degree of sequence variation was observed within TW10 in children compared with adults, based on an expanded analysis of 103 published (17, 20) and unpublished sequences from B57/5801-positive adults infected with clade B HIV-1 (Fig. 6). Selection has driven more than two nonsynonymous nucleotide substitutions in a significantly higher proportion of children (6 of 21) than adults (10 of 103; p = 0.03), resulting in either triple amino acid substitutions or more complex substitutions such as G248T and G248Q, which require multiple nucleotide changes. The higher degree of escape within the TW10 epitope in pediatric infection is consistent with the observation that variant-specific CTL are generated in children, which are themselves capable of driving further escape.
|
| Discussion |
|---|
|
|
|---|
Mutational escape from an established CTL response is of lasting advantage to the virus only if the host is subsequently unable to mount an efficient immune response to the variant epitope. In this regard, it is important to consider why adult subjects are generally unable to respond to variant epitopes following escape, despite the proven immunogenicity of these variants in children. One possible explanation is that a phenomenon akin to "original antigenic sin," originally described in the humoral response to influenza, may be at play in the cellular immune response (22, 23). Extension of the original antigenic sin paradigm to CTLs was first suggested in studies of lymphocytic choriomeningitis virus-infected mice, in which an existing CTL response appeared to limit the ability of the immune system to recognize a closely related variant epitope (22). More recently, a similar phenomenon was described in the response to recurrent dengue viral infection of humans (23). If human CTLs are indeed constrained in their ability to recognize emerging viral variants, this would have important implications for the immune response to a continually evolving chronic viral infection such as HIV-1. Although the mechanism of original antigenic sin in the CTL response is not clear, it has been suggested that the relative proportion of naive and memory cells may play a role (24) because the likelihood of a HLA-peptide complex encountering a naive T cell of appropriate specificity may be lower than the likelihood of encountering a weakly cross-reactive memory T cell. If this is the case, then original antigenic sin may be less apt to occur in children, who possess a relative abundance of naive T cells. It should be noted that in our study, children were not only more likely than adults to recognize the escape variant but also less likely to demonstrate a persistent ex vivo response to wild-type epitope following escape. Nearly half of adult subjects continued to recognize the wild-type TW10 epitope after its disappearance from the plasma. It is possible that the escape variants act as altered peptide ligands, boosting the response to the original epitope via cross-recognition by wild-type TW10-specific CTL, yet fail to sensitize cells for efficient lysis by CTL or even antagonize the wild-type-specific T cells (25). Such cross-reactive boosting may be fundamental to the mechanism of original antigenic sin (24).
The failure of TW10 escape mutations to back-revert in the presence of a variant-specific CTL response poses an interesting paradox. After the CTL population, which originally drove selection of the escape mutants, has declined to the extent that it is no longer detectable ex vivo and has been eclipsed by a variant-specific CTL response of much higher frequency, one might expect that it would be advantageous for the virus to revert to its original sequence. The factors governing the likelihood of reversion of escape mutations are likely to be multiple and complex (17) and include the impact on viral replicative fitness and the presence of compensatory mutations. A more direct explanation for the lack of reversion in the present case is suggested by the persistence in memory of a low-frequency T cell population specific for the wild-type epitope, confirmed by our ability to grow out a wild-type-specific CTL clone more than 2 years following escape. This memory CTL population might conduct surveillance and lyse revertant virus with high efficiency, despite the fact that it is of such low frequency that a response is not detectable ex vivo (21). In support of this hypothesis, recent studies in the macaque model have demonstrated that although engineered CTL escape mutations revert following transmission to a MHC-mismatched host, reversion fails to occur after inoculation into an animal who shares the restricting MHC allele, even though no response to the epitope can be demonstrated ex vivo (26). The recent demonstration that mutations within TW10 revert to wild-type upon transmission to a B57/B5801-negative host (17) suggests that a similar force, presumably a low-frequency wild-type-specific CTL response, may prevent reversion of TW10 in these B57-positive children.
The potential implications of these data for vaccine design are mixed. On the positive side, these observations suggest that a strategy of dual vaccination with both an epitope and its common variants may mitigate the consequences of viral escape. Our data indicate that such a strategy may be more efficacious in children than adults. Moreover, therapeutic vaccination of HIV-infected children may be effective in inducing a variant-specific response that could avert positive selection of escape variants as they arise. On the negative side, the low degree of variant-specific recognition among adult subjects underscores the sobering possibility that successful induction of vaccine-specific responses to variable epitopes may do more harm than good if the vaccine-specific response interferes with recognition of variant epitopes present in circulating viral strains.
In conclusion, the present data demonstrate that escape from the CTL response is frequent during infancy among subjects expressing the HLA-B57 allele. Moreover, the developing immune system may display greater plasticity in recognizing viral variants as they arise. Such adaptability of the immune response may present a considerable advantage in the containment of a continually evolving chronic viral infection such as HIV-1. These observations may open the door to vaccine strategies involving simultaneous vaccination with both optimal HIV-1 epitopes and predicted escape variants, because original antigenic sin may be less of a barrier to this approach in children than in adults.
| Acknowledgments |
|---|
| Disclosures |
|---|
|
|
|---|
| Footnotes |
|---|
1 This work was supported by the National Institutes of Health Grant K23-AI52078 (to M.E.F.), the Charles H. Hood Foundation (to M.E.F.), and the Elizabeth Glaser Pediatric AIDS Foundation (to M.E.F., P.J.R.G.). P.J.R.G. is an Elizabeth Glaser Scientist. B.D.W. is a Doris Duke Distinguished Clinical Scientist and a Howard Hughes Investigator. ![]()
2 Address correspondence and reprint requests to Dr. Margaret E. Feeney, 149 13th Street, 5th Floor, Charlestown, MA 02129. E-mail address: mfeeney{at}partners.org ![]()
3 Abbreviation used in this paper: HAART, highly active antiretroviral therapy. ![]()
Received for publication January 21, 2005. Accepted for publication April 6, 2005.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
H. Streeck, B. Li, A. F.Y. Poon, A. Schneidewind, A. D. Gladden, K. A. Power, D. Daskalakis, S. Bazner, R. Zuniga, C. Brander, et al. Immune-driven recombination and loss of control after HIV superinfection J. Exp. Med., July 14, 2008; (2008) jem.20080281. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. J. Maness, L. J. Yant, C. Chung, J. T. Loffredo, T. C. Friedrich, S. M. Piaskowski, J. Furlott, G. E. May, T. Soma, E. J. Leon, et al. Comprehensive Immunological Evaluation Reveals Surprisingly Few Differences between Elite Controller and Progressor Mamu-B*17-Positive Simian Immunodeficiency Virus-Infected Rhesus Macaques J. Virol., June 1, 2008; 82(11): 5245 - 5254. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. F. Thobakgale, D. Ramduth, S. Reddy, N. Mkhwanazi, C. de Pierres, E. Moodley, W. Mphatswe, N. Blanckenberg, A. Cengimbo, A. Prendergast, et al. Human Immunodeficiency Virus-Specific CD8+ T-Cell Activity Is Detectable from Birth in the Majority of In Utero-Infected Infants J. Virol., December 1, 2007; 81(23): 12775 - 12784. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Ueno, Y. Idegami, C. Motozono, S. Oka, and M. Takiguchi Altering Effects of Antigenic Variations in HIV-1 on Antiviral Effectiveness of HIV-Specific CTLs J. Immunol., May 1, 2007; 178(9): 5513 - 5523. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Gros, M. Pelegrin, M. Plays, and M. Piechaczyk Efficient Mother-to-Child Transfer of Antiretroviral Immunity in the Context of Preclinical Monoclonal Antibody-Based Immunotherapy. J. Virol., October 1, 2006; 80(20): 10191 - 10200. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. R. Bailey, T. M. Williams, R. F. Siliciano, and J. N. Blankson Maintenance of viral suppression in HIV-1-infected HLA-B*57+ elite suppressors despite CTL escape mutations J. Exp. Med., May 15, 2006; 203(5): 1357 - 1369. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Zhang, J. Fu, Q. Zhao, Y. He, L. Jin, H. Zhang, J. Yao, L. Zhang, and F.-S. Wang Differential Restoration of Myeloid and Plasmacytoid Dendritic Cells in HIV-1-Infected Children after Treatment with Highly Active Antiretroviral Therapy J. Immunol., May 1, 2006; 176(9): 5644 - 5651. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Martinez-Picado, J. G. Prado, E. E. Fry, K. Pfafferott, A. Leslie, S. Chetty, C. Thobakgale, I. Honeyborne, H. Crawford, P. Matthews, et al. Fitness Cost of Escape Mutations in p24 Gag in Association with Control of Human Immunodeficiency Virus Type 1. J. Virol., April 1, 2006; 80(7): 3617 - 3623. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. H. O'Connor and D. R. Burton Immune responses and HIV: a little order from the chaos J. Exp. Med., March 20, 2006; 203(3): 501 - 503. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |